Pharmaceutical

AriBio licenses Alzheimer’s pill in China for up to $770m

An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.6bn by 2030

Mar 26, 2024 - 00:00
AriBio licenses Alzheimer’s pill in China for up to $770m
An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.6bn by 2030
Read the original article

Tags:

Previous Article

Esperion snags US label expansion for cardiovascular disease drugs

Next Article

Birmingham University to develop lollipop for mouth cancer detection

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: U.S. Senate committee passes PBM bills; Pfizer CEO predicts pharma will sue over Medicare price negotiations

STAT+: Pharmalittle: U.S. Senate committee passes PBM b...

May 13, 2023

STAT+: Medicare has a new plan to address drug shortages — but it could backfire

STAT+: Medicare has a new plan to address drug shortage...

Jul 18, 2023

Over half of world’s population not covered by essential healthcare services

Over half of world’s population not covered by essentia...

Sep 23, 2023